Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn

Sep 2, 2026, 3:06 PM

Read Full Article → Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn

Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn

Translate article text

Choose a language and wait for the translated text.

The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential.

Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn | PharmaVoice